In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with the CEO of Auris Medical, Thomas Meyer. They cover the company’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of antipsychotic medication.

In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Eric A. Adams, the CEO of InMed Pharmaceuticals, the Canada-based biopharmaceutical company focused on maximizing the therapeutic potential of cannabinoids.

In this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with the CEO of Quantum Genomics, Jean-Philippe Milon. They cover Quantum Genomics’ programs in hypertension and heart failure, the data so far and the road ahead.

In this episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, has an in-depth discussion with Evan Jones, the CEO of OpGen. Topics include OpGen’s products and the company's focus on revolutionising the identification and treatment of bacterial infections, as well as the announced merger with Curetis.

n this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with the CEO of Auris Medical, Thomas Meyer. They cover Auris Medical’s development programs for intranasal betahistine for acute vertigo as well as to treat some of the major side effects of antipsychotic medication.

In this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with the CEO of Carmat, Stéphane Piat. They cover Carmat’s total artificial heart, the technology and plans for development and commercialization, as well as the patients' experiences with the device to date.

In this episode of Edison Talks, Edison’s director of research for North America, Maxim Jacobs, has an in-depth discussion with Photocure’s CEO, Daniel Schneider. They cover Photocure’s marketed bladder cancer diagnostic product Hexvix/Cysview, its data and potential for growth in the United States and the prospects for future competition.